ALIGOS Therapeutics
Infectious Disease Therapeutics · Biotechnology
Visa sponsorship
1
H-1B filings in 12 months
$248k
Median offered salary
0
Open roles in United States
Who they sponsor
Natural sciences managers
1
In the register as Aligos Therapeutics, Inc., South San Francisco, CA
Other sponsors in the same field
Daiichi Sankyo 
Kashiv Biosciences 
Veranova
Alert me
US Department of Labor · latest filing Feb 24, 2026 · Visa details by country
People
Sushmita Chanda
Executive Officer
Julian Symons
Executive Officer
Brian Dowd
Executive Officer
Lucinda Quan
Executive Officer
Leonid Beigelman
Executive Officer, Director
Lawrence Blatt
Executive Officer, Director
John Fry
Executive Officer
Lesley Calhoun
Executive Officer
Matthew McClure
Executive Officer
Hardean Achneck
Executive Officer
Peter Hirth
Director
Carole Neuchterlein
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Wellington ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial
The post ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial appeared first on ALIGOS Therapeutics.
Read more
Report
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Detailed price information for Aligos Therapeutics Inc (ALGS-Q) from The Globe and Mail including charting and trades.
Read more
Report
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
--Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has received the upfront payment of $25 M USD from the excl
Read more
Report
Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists
The post Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists appeared first on ALIGOS Therapeutics.
Read more
Report
The potentially best-in-class HBV ASO ALG-170674 demonstrates additive to synergistic antiviral activities when combined with other anti-HBV modalities
The post The potentially best-in-class HBV ASO ALG-170674 demonstrates additive to synergistic antiviral activities when combined with other anti-HBV modalities appeared first on ALIGOS Therapeutics.
Read more
Report
ALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development
The post ALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development appeared first on ALIGOS Therapeutics.
Read more
Report
Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cell-based experiments
The post Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cell-based experiments appeared first on ALIGOS Therapeutics.
Read more
Report
Antisense oligonucleotide-based strategy to target hepatitis delta virus infections
The post Antisense oligonucleotide-based strategy to target hepatitis delta virus infections appeared first on ALIGOS Therapeutics.
Read more
Report
Discovery of novel HDV entry inhibitors with selectivity over bile acid inhibition
The post Discovery of novel HDV entry inhibitors with selectivity over bile acid inhibition appeared first on ALIGOS Therapeutics.
Read more
Report
Preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor for the treatment of chronic hepatitis B infection and liver cancer
The post Preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor for the treatment of chronic hepatitis B infection and liver cancer appeared first on ALIGOS Therapeutics.
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
South San Francisco
United States
HQ
US Office